31 January 2022
Latham & Watkins Advises Homology Medicines, Inc. in a Newly Formed AAV Manufacturing and Innovation Business with Oxford Biomedica
Advising firms
Deal team
20 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Matthew Goulding Lead | Latham & Watkins LLP | Partner | corporate | Not stated |
| Peter Handrinos Lead | Latham & Watkins LLP | Partner | corporate | Not stated |
| Phil Rossetti Lead | Latham & Watkins LLP | Partner | corporate | Not stated |
| Judith Hasko Lead | Latham & Watkins LLP | Partner | licensing | Not stated |
| Andrew Barris | Latham & Watkins LLP | Associate | corporate | Not stated |
| Gregory Drozdzal | Latham & Watkins LLP | Associate | corporate | Not stated |
| Cory Lewis | Latham & Watkins LLP | Associate | corporate | Not stated |
| Nicole McNeil | Latham & Watkins LLP | Associate | corporate | Not stated |
| Kristin Rulison | Latham & Watkins LLP | Associate | corporate | Not stated |
| Eliot Choy | Latham & Watkins LLP | Counsel | licensing | Not stated |
| Robert Yeh | Latham & Watkins LLP | Associate | licensing | Not stated |
| Seth Appiah-Opoku | Latham & Watkins LLP | Associate | licensing | Not stated |
| Arun Mohan | Latham & Watkins LLP | Associate | licensing | Not stated |
| Stephanie Fontanes | Latham & Watkins LLP | Partner | real estate | Not stated |
| Matthew Conway | Latham & Watkins LLP | Partner | employee benefits and compensation | Not stated |
| Kirk Porter | Latham & Watkins LLP | Associate | employee benefits and compensation | Not stated |
| Katharine Moir | Latham & Watkins LLP | Partner | tax | Not stated |
| Alexander Farris | Latham & Watkins LLP | Associate | tax | Not stated |
| Mandy Reeves | Latham & Watkins LLP | Partner | antitrust | Not stated |
| Patrick English | Latham & Watkins LLP | Counsel | antitrust | Not stated |
Stated terms
- Stated value
- USD 130m (US$130 million)
- What the figure measures
- Total transaction value
- Client
- Homology Medicines, Inc.Joint venture party
- Counterparties
- Oxford Biomedica plc (Joint venture party)